These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20427625)

  • 1. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.
    Lu YJ; Yadav P; Clements JD; Forte S; Srivastava A; Thompson CM; Seid R; Look J; Alderson M; Tate A; Maisonneuve JF; Robertson G; Anderson PW; Malley R
    Clin Vaccine Immunol; 2010 Jun; 17(6):1005-12. PubMed ID: 20427625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide.
    Lu YJ; Forte S; Thompson CM; Anderson PW; Malley R
    Infect Immun; 2009 May; 77(5):2076-83. PubMed ID: 19255193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.
    Xu X; Meng J; Wang Y; Zheng J; Wu K; Zhang X; Yin Y; Zhang Q
    J Microbiol; 2014 Apr; 52(4):315-23. PubMed ID: 24682994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.
    Malley R; Lipsitch M; Stack A; Saladino R; Fleisher G; Pelton S; Thompson C; Briles D; Anderson P
    Infect Immun; 2001 Aug; 69(8):4870-3. PubMed ID: 11447162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.
    Greene CJ; Marks LR; Hu JC; Reddinger R; Mandell L; Roche-Hakansson H; King-Lyons ND; Connell TD; Hakansson AP
    Infect Immun; 2016 Jun; 84(6):1693-1703. PubMed ID: 27001538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.
    Jakobsen H; Schulz D; Pizza M; Rappuoli R; Jónsdóttir I
    Infect Immun; 1999 Nov; 67(11):5892-7. PubMed ID: 10531245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant.
    Malley R; Morse SC; Leite LC; Areas AP; Ho PL; Kubrusly FS; Almeida IC; Anderson P
    Infect Immun; 2004 Jul; 72(7):4290-2. PubMed ID: 15213177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.
    Pimenta FC; Miyaji EN; Arêas AP; Oliveira ML; de Andrade AL; Ho PL; Hollingshead SK; Leite LC
    Infect Immun; 2006 Aug; 74(8):4939-44. PubMed ID: 16861686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine.
    Campos IB; Herd M; Moffitt KL; Lu YJ; Darrieux M; Malley R; Leite LC; Gonçalves VM
    Vaccine; 2017 Mar; 35(9):1306-1315. PubMed ID: 28161422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced safety and immunogenicity of a pneumococcal surface antigen A mutant whole-cell inactivated pneumococcal vaccine.
    David SC; Laan Z; Minhas V; Chen AY; Davies J; Hirst TR; McColl SR; Alsharifi M; Paton JC
    Immunol Cell Biol; 2019 Sep; 97(8):726-739. PubMed ID: 31050022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.
    Jakobsen H; Bjarnarson S; Del Giudice G; Moreau M; Siegrist CA; Jonsdottir I
    Infect Immun; 2002 Mar; 70(3):1443-52. PubMed ID: 11854231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
    Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
    Vaccine; 2016 Nov; 34(48):5968-5974. PubMed ID: 27771185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotype-Independent Protection Against Invasive Pneumococcal Infections Conferred by Live Vaccine With
    Jang AY; Ahn KB; Zhi Y; Ji HJ; Zhang J; Han SH; Guo H; Lim S; Song JY; Lim JH; Seo HS
    Front Immunol; 2019; 10():1212. PubMed ID: 31191555
    [No Abstract]   [Full Text] [Related]  

  • 18. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.
    Lu YJ; Leite L; Gonçalves VM; Dias Wde O; Liberman C; Fratelli F; Alderson M; Tate A; Maisonneuve JF; Robertson G; Graca R; Sayeed S; Thompson CM; Anderson P; Malley R
    Vaccine; 2010 Nov; 28(47):7468-75. PubMed ID: 20858450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
    Salcedo-Rivillas C; Debrie AS; Miyaji EN; Ferreira JM; Raw I; Locht C; Ho PL; Mielcarek N; Oliveira ML
    Clin Vaccine Immunol; 2014 Jul; 21(7):972-81. PubMed ID: 24807055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal immunization with recombinant chimeric pneumococcal protein and cell wall from immunobiotic bacteria improve resistance of infant mice to Streptococcus pneumoniae infection.
    Laiño J; Villena J; Suvorov A; Zelaya H; Ortiz Moyano R; Salva S; Alvarez S
    PLoS One; 2018; 13(11):e0206661. PubMed ID: 30395582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.